Clik here to view.
Seagen and Astellas Announce Updated Results from Two Trials of PADCEV®...
BOTHELL, Wash. & TOKYO Seagen Inc. (Nasdaq:SGEN) and Astellas Pharma Inc. (TSE: 4503, President and CEO: Kenji Yasukawa, Ph.D., “Astellas”) today announced updated results from two clinical...
View ArticleClik here to view.
BeiGene to Showcase Broad Clinical Portfolio at 2021 ASCO Annual Meeting
CAMBRIDGE, Mass. & BEIJING BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160), a global biotechnology company focused on developing and commercializing innovative medicines worldwide, today announced...
View ArticleClik here to view.
Takeda to Present Positive Primary Analysis from Phase 2 OPTIC Trial of...
OSAKA, Japan & CAMBRIDGE, Mass. Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) (“Takeda”) today announced that primary analysis data from the Phase 2 OPTIC (Optimizing Ponatinib...
View ArticleClik here to view.
Takeda Presents Updated Results for Mobocertinib, Further Substantiating the...
OSAKA, Japan & CAMBRIDGE, Mass. Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) (“Takeda”) today announced updated data from the Phase 1/2 trial of mobocertinib (TAK-788) orally...
View ArticleClik here to view.
Japan’s Ministry of Health, Labour and Welfare (MHLW) Approves Moderna’s...
CAMBRIDGE, Mass. Moderna, Inc. (Nasdaq: MRNA), a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines, today announced that the Ministry of Health, Labour and Welfare...
View ArticleClik here to view.
U.S. Food & Drug Administration Grants Priority Review of Maribavir for the...
OSAKA, Japan Takeda Pharmaceutical Company Limited Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) (“Takeda”) today announced that the U.S. Food & Drug Administration (FDA) has...
View ArticleClik here to view.
BeiGene Announces Positive Topline Results from Phase 3 Trial of Tislelizumab...
CAMBRIDGE, Mass. & BEIJING BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160), a global biotechnology company focused on developing and commercializing innovative medicines worldwide, today announced...
View ArticleClik here to view.
ITO CO., LTD. Has Received Clearance From the U.S. Food and Administration...
KAWAGUCHI, Japan ITO CO., LTD. (Head office: Kawaguchi-shi) a pioneer of electrophysical agents in Japan, announces that its Electrical Muscle Stimulator for TMJ Pain Relief “D function” has...
View ArticleClik here to view.
武田呈报mobocertinib的最新结果，进一步证实EGFR外显子20插入+ mNSCLC患者的临床收益
日本大阪和马萨诸塞州剑桥 (美国商业资讯)–武田药品工业株式会社(TSE:4502/NYSE:TAK)（简称“武田”）今天发布mobocertinib...
View ArticleClik here to view.
知临集团：针对金黄色葡萄球菌的ALS-4临床I期试验中期分析取得阳性进展，针对神经母细胞瘤的SACT-1新药临床试验申报前准备取得阳性进展
纽约和伦敦和巴黎 (美国商业资讯)–监管新闻： 临床阶段生物制药公司知临集团（Aptorum Group...
View ArticleClik here to view.
Voxeldance Strengthens Executive Team with Key Hire
SAN RAMON, Calif. Voxeldance, a leading provider of digital manufacturing software for additive 3D printing, today announced the appointment of Robert Yusin as Chief Operating Officer. This press...
View ArticleClik here to view.
Oral-B Encourages Consumers to Brush up on Their Oral Care Regimen and...
LONDON Oral-B has teamed up with Scientific American and its Custom Media Division (SACM) to explore the latest research connecting oral health and overall health; as many are unaware of the impact...
View ArticleClik here to view.
Engine Biosciences宣布获得超额认购的4300万美元A轮融资，以通过机器学习和新一代组合遗传学破译新药开发遗传密码
新加坡和美国加利福尼亚州圣卡洛斯 Engine Biosciences（“Engine”）于今日宣布成功完成超额认购的4300万美元A轮融资。Engine公司能识别出复杂疾病遗传密码中的错误，并用精确的治疗方案对其进行修复。本轮融资由Polaris...
View ArticleClik here to view.
知临集团首席执行官认购本公司股份
纽约、伦敦和巴黎 (美国商业资讯)–知临集团（纳斯达克股票代码：APM，巴黎泛欧证券交易所代码：APM）（「知临集团」或「知临」），是一家临床阶段的生物制药公司，致力于开发新型疗法以解决全球尚未满足的医疗需求，今天宣布公司创始人，首席执行官兼执行董事禤骏远先生通过其全资投资公司Jurchen Investments...
View ArticleClik here to view.
Engine Biosciences Announces $43 Million Series A Round to Decipher Genetic...
SINGAPORE & SAN CARLOS, Calif. Engine Biosciences (“Engine”) today announced the successful completion of an oversubscribed $43 million Series A funding round. Engine identifies errors in the...
View ArticleClik here to view.
Orum Therapeutics Appoints Jae Won Kim Chief Financial Officer
BOSTON & DAEJEON, South Korea Orum Therapeutics, a global biotech company pioneering the development technologies for precision delivery of targeted protein degraders to treat cancer, today...
View ArticleClik here to view.
CORRECTING AND REPLACING Oral-B & Crest Encourage Consumers to Brush up on...
LONDON Please replace the release with the following corrected version due to multiple revisions. The updated release reads: ORAL-B & CREST ENCOURAGE CONSUMERS TO BRUSH UP ON THEIR ORAL CARE...
View ArticleClik here to view.
武田薬品、EGFRエクソン20挿入変異を伴うmNSCLC患者における臨床効果をさらに裏付けるモボセルチニブの最新結果を発表へ
大阪 & 米マサチューセッツ州ケンブリッジ （ビジネスワイヤ） —...
View ArticleClik here to view.
ONK Therapeutics Secures Exclusive Global License to Patent for CISH Knockout...
GALWAY, Ireland & SAN DIEGO, USA ONK Therapeutics Ltd, an innovative natural killer (NK) cell therapy company, today announced that it has entered into an exclusive global patent license...
View ArticleClik here to view.
Available Now! Whitepaper: Advancing Drug Discovery Through DNA Encoded...
CHENGDU, China HitGen and Fierce Biotech jointly release the Whitepaper: Advancing Drug Discovery through DNA-Encoded Library (DEL) Technology today. This whitepaper will provide the drug discovery...
View Article